PAM Q1 2026 Earnings Staggering EPS Beat as Operating Performance Surges Xenetic Biosciences Q2 2025 Earnings Narrowed Loss Exceeds Expectations Amid Oncology Pipeline Progress 60 Degrees Pharmaceuticals Inc SXTP Q1 2026 Earnings EPS Misses Estimates No Revenue Yet MCRB Q1 2026 Earnings EPS Misses Estimates Stock Declines 417 EVGO Q1 2026 Earnings NarrowerThanExpected Loss Highlights Operational Discipline MGPI Q1 2026 Earnings Significant EPS Beat Bolstered by Operational Efficiency